Document
IPR2023-00724, No. 2411 Exhibit - EX2411 Kombiglyze® XR Prescribing Information rev Feb 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2411 Exhibit - EX2411 Kombiglyze® XR Prescribing Information rev Feb 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2475 Exhibit - EX2475 Mounjaro Prescribing Information rev July 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2475 Exhibit - EX2475 Mounjaro Prescribing Information rev July 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2522 Exhibit - EX2522 Novo Nordisk, Ozempic semaglutide injection 05 mg, 1 mg, or 2 mg WAC Price, httpswwwnovopricingcomozempichtml, last updated Oct 2023 (P.T.A...
Cite Document
IPR2023-00724, No. 2522 Exhibit - EX2522 Novo Nordisk, Ozempic semaglutide injection 05 mg, 1 mg, or 2 mg WAC Price, httpswwwnovopricingcomozempichtml, last updated Oct 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2512 Exhibit - EX2512 Novo Nordisk, Financial report for the period 1 January 2022 to 30 September 2022 Nov 2, 2022 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2512 Exhibit - EX2512 Novo Nordisk, Financial report for the period 1 January 2022 to 30 September 2022 Nov 2, 2022 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2051-2 Exhibit - EX2051 Declaration of Anne Flint, Ph D REDACTED (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2051-2 Exhibit - EX2051 Declaration of Anne Flint, Ph D REDACTED (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2087 Exhibit - EX2087 ADA Standards of Medical Care, Cardiovascular Disease and Risk Management Standards of Medical Care in Diabetes, Diabetes Care 45Suppl 1S1...
Cite Document
IPR2023-00724, No. 2087 Exhibit - EX2087 ADA Standards of Medical Care, Cardiovascular Disease and Risk Management Standards of Medical Care in Diabetes, Diabetes Care 45Suppl 1S144–S175 2022 (P.T.A
+ More Snippets
Document
IPR2023-00724, No. 2459 Exhibit - EX2459 Xultophy 10036 Prescribing Information rev Nov 2016 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2459 Exhibit - EX2459 Xultophy 10036 Prescribing Information rev Nov 2016 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1120 Exhibit - Exhibit 1120 Saxenda Orange Book (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1120 Exhibit - Exhibit 1120 Saxenda Orange Book (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1302 Exhibit - Exhibit 1302 Speigel Decl (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1302 Exhibit - Exhibit 1302 Speigel Decl (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1103 Exhibit - Exhibit 1103 Saxenda label (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1103 Exhibit - Exhibit 1103 Saxenda label (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1124 Exhibit - Exhibit 1124 GRADE (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1124 Exhibit - Exhibit 1124 GRADE (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1128 Exhibit - Exhibit 1128 Proposed order (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1128 Exhibit - Exhibit 1128 Proposed order (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1118 Exhibit - Exhibit 1118 (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1118 Exhibit - Exhibit 1118 (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2435 Exhibit - EX2435 US Food Drug Administration, DrugsFDA, Farxiga® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2435 Exhibit - EX2435 US Food Drug Administration, DrugsFDA, Farxiga® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2402 Exhibit - EX2402 US Food Drug Administration, DrugsFDA, Janumet® XR (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2402 Exhibit - EX2402 US Food Drug Administration, DrugsFDA, Janumet® XR (P.T.A.B. Jan. 17, 2024)
+ More Snippets